6 Psychedelic Clinical Trials That Could Have A Major Impact On The Way We Address Mental HealthPsyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, PPsyched Wellness Is Laser Focused On Uncovering The Medical Properties Associated With MuscimolField Trip Health Has Its Sights Set On Jamaica To Spearhead Future R&D InitiativesPure Extracts Submits Multiple SKUs to Health Canada for ApprovalTryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post ListingNuminus Wellness Is Making Major Headway On Its MDMA TrialsPsyched Wellness Closes $6,603,000 Bought Deal Private PlacementMind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with PsychedelicsTryp Therapeutics Completes $2 Million Strategic FinancingCybin Inc. Is Focused On Taking A Quantitative Approach To Tackling DepressionTryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing ProgramTryp Therapeutics Appoints Dr. Joel Castellanos as Clinical AdvisorField Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica3 Functional Mushroom Leaders Investors Need To Be WatchingTryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer MillerNuminus Wellness Completes Acquisition of Montreal-based Mindspace WellbeingTryp Therapeutics Announces Strategic Investment of $2,000,000Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching
Back

Pure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction Platform

Jan 7, 2021 • 9:19 AM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

In December, we highlighted Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) after it was granted a Standard Processing License by Health Canada in late September. The plant-based extraction company is levered to the cannabis and the psychedelic extract market and we consider it to be a differentiated story with attractive growth prospects.

The plant-based extraction company operates a state-of-the-art facility that has been constructed to European Union GMP (EU GMP) standards. By constructing the facility to these standards, the company will be able to export products and formulations to the EU, in markets where it’s legal. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada

Today, we want to issue an update on Pure Extracts after the company announced a series of positive developments. During the last month, the plant-based extraction company has applied for a Dealer’s License, announced plans to raise additional capital, and has focused on forming strategic partnerships with leading operators in the cannabis and the psychedelic sector.

Starts Construction on the Fourth Unit of its Facility

Last week, Pure Extracts announced an important milestone and started the buildout of the fourth unit of its state-of-the-art facility. The unit will be used for mushroom extraction and for the research and development of psilocybin once Pure Extracts is granted a Dealer’s License from Health Canada.

We are of the opinion that the granting of a Dealer’s License represents the most significant potential near-term catalyst for Pure Extracts. A Dealer’s License provides the framework for legal access to controlled substances, and the control and regulation of production, distribution and sale of psilocybin.

Under this framework, the license dictates the activities, conditions, and restrictions for the license holder (depending on license permissions). The granting of a Dealer’s License could allow Pure Extracts to conduct the following activities:

  1. Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
  2. Research and manufacture of controlled substances such as psilocybin and psilocin
  3. Business to business sale of controlled substances, including by export
  4. Sale of controlled substance via pharmacies

An Emerging Growth Story that has Significant Growth Catalysts

One of the reasons we are excited about Pure Extracts is related to the expansion potential that is associated with the existing facility. The company owns property that is located adjacent to its state-of-the-art facility which has been constructed to meet Health Canada standards. The management team expects this space to mimic the current facility and we are favorable on this due to the amount of revenue that can be generated through it.

In the first quarter of 2021, Pure Extracts expects to launch a variety of premium functional mushroom products. We are bullish on the strategy that is associated with the product launch and expect to see them gain traction with consumers. The launch should prove to be a catalyst for growth and is an important aspect of the story as it relates to the near-term outlook.

Another reason we are excited about Pure Extracts is related to its ability to conduct research and development on psychedelic compounds like psilocybin and psilocin. From a partnership standpoint, this ability provides Pure Extracts with an attractive avenue for growth and will prepare it to work with medical doctors, pharmaceutical companies, and pharmacies as late-stage clinical trials are being conducted by several psychedelic therapy firms. We are favorable on the potential value that can be generated for Pure Extracts over the long-term and will monitor how this aspect of the story advances in 2021.

A Multi-Faceted Expansion Story in the Making

We believe that Pure Extracts represents a multi-faceted growth opportunity and are favorable on the leverage that it has to the cannabis, functional mushroom, and psychedelic extract market. The company has been executing flawlessly and we are favorable on the direction the management is bringing the business.

If you are interested in learning more about Pure Extracts, please send an email to support@technical420.com with the subject “Pure Extracts” to be added to our distribution list.

 

 

 

 

 

 

 

 

 

 

 

 

Pursuant to an agreement between StoneBridge Partners LLC and Pure Extracts Technologies Corp. we have been hired for a period of 180 days beginning November 1, 2020 and ending May 1, 2020 to publicly disseminate information about (PULL) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (PULL) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own one hundred seventy six thousand eight hundred and twenty nine (176,829) shares of (PULL), which we purchased via private placement. We plan to sell the “ZERO” shares of (PULL) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (PULL) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link